A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.
Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.
Topical melatonin was found to significantly increase hair density and decrease scalp conditions like seborrheic dermatitis. The user is considering using it alongside finasteride and oral minoxidil for treating hair loss and scalp health.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The conversation is about a user experiencing increased hair loss after altering their treatment routine of oral dutasteride and topical minoxidil. The dermatologist emphasized the importance of diet and vitamins, but the user is skeptical given their healthy lifestyle.
A user shared their experience with telogen effluvium triggered by a keratin treatment, leading to significant hair loss. They found improvement using aloe vera with rosemary, a protein and iron-rich diet, and patience.
Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.
Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
Minoxidil 5% topical solution may cause eyesight problems, with some users experiencing blurred vision. The discussion also mentions finasteride's potential side effects, including erectile dysfunction, with varied personal experiences.
Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.
The conversation discusses using homemade topical finasteride for hair loss, showing an increase in DHT levels despite treatment. The user applies 0.125mg daily, resulting in 113.4% of previous DHT levels.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
The user is experiencing hair thinning and has been using minoxidil, dutasteride mesotherapy, and red light therapy for 4.5 months without seeing results. They are considering changing their treatment due to lack of progress.
Tocotrienols are being discussed as a potential treatment for hair regrowth, but users report no noticeable effects after several months of use. Some users are combining tocotrienols with other treatments like pumpkin seed oil and peppermint and rosemary oil.
The conversation is about hair regrowth using topical finasteride, minoxidil, and microneedling, with some users noticing new hair growth. The original poster also takes protein, biotin, and vitamin D supplements and prefers topical treatments due to concerns about side effects from oral finasteride.
Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.
Focus on scalp health, not just DHT suppression, is crucial for hair regrowth. Effective treatments include Hair Restoration shampoo, LLLT laser cap, microneedling, and topical finasteride.
A user shared their disappointing results after 1.5 years of hair treatments, including a hair transplant, finasteride, minoxidil, PRP, vegan shampoo, and more. They are considering switching to dutasteride, oral minoxidil, and improving their microneedling routine.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.